Outcomes are still associated to operator experience and institutional volume

This study is a retrospective analysis of 2,243,209 PCI stenting procedures in the USA between 2005 and 2009. During this period, a reduction in the number of PCI procedures was observed (also observed globally) from 53 in previous years to 33 procedures per operator per year, and from 1,024 to 693 per hospital per year.

 

Primary end point was in-hospital mortality and secondary end point was a composite of in-hospital mortality and peri-procedural complications.

 

Overall in-hospital mortality was 1.08% and peri-procedural complications rate was 7.10%, most common being vascular complications (2.01%), followed by cardiac complications (1.76%), respiratory failure (1.50%) and postoperative stroke (0.99%).

 

After adjustment for potential confounders, it was observed that In-hospital mortality and peri-procedural complications both increased significantly as PCI volume at operator level declined.

 

The chance of death or complications doubles among those operators with ≤15 PCIs a year, compared to those with >100 PCIs a year (10.1% vs 5.1% respectively; p<0.001). Operator volume also reduces in-hospital stay and associated costs.

 

Initially, a similar relationship was observed between outcomes and institutional volume; however, after adjusting by operator volume, the observed difference was considered non-significant.

 

Conclusion

In-hospital mortality rate in the context of PCI is low. The higher the number of procedures by operator, the lower mortality, complications, in-hospital stay and costs. 

 

Editorial Comment

Is there a magic number that will turn operators into experts? The last 2013 ACCF/AHA/SCAI issue recommended at least 50 PCIs a year per operator and 200 per center, and this is an amendment to the previous document that had recommended 75 per operator, a reasonable change given the decreasing number of procedures.

 

The study showed that an important number of operators did not reach the 50 annual procedures, which could be a problem for future PCIs, if this global decreasing tendency continues in the context of a clear relationship between outcomes and volume.

 

Original title: Impact of annual operator and institutional volume on percutaneous coronary intervention outcomes: a 5-year United States experience (2005-2009). 

Reference: Badheka AO et al. Circulation. 2014; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...